Flucelvax Quad Quadrivalent influenza vaccine (surface antigen  inactivated) suspension for injection pre-filled syringe with attached needle Australië - Engels - Department of Health (Therapeutic Goods Administration)

flucelvax quad quadrivalent influenza vaccine (surface antigen inactivated) suspension for injection pre-filled syringe with attached needle

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Flucelvax Quad Quadrivalent influenza vaccine (surface antigen, inactivated), suspension for injection pre-filled syringe needle free Australië - Engels - Department of Health (Therapeutic Goods Administration)

flucelvax quad quadrivalent influenza vaccine (surface antigen, inactivated), suspension for injection pre-filled syringe needle free

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

NOBILIS INFLUENZA H5N2 Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nobilis influenza h5n2

department of agriculture, fisheries and forestry - inactivated avian influenza virus type a, h5n2 - misc. vaccines or anti sera - inactivated avian influenza virus type a, h5n2 vaccine active 0.0 undefined - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - avian influenza h5 | h5 | virus veterinary

DURAMUNE ADULT C4 CANINE DISTEMPER, ADENOVIRUS, PARAINFLUENZA & PARVOVIRUS LIVE VACCINE Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

duramune adult c4 canine distemper, adenovirus, parainfluenza & parvovirus live vaccine

boehringer ingelheim animal health australia pty. ltd. - canine adeno virus type 2; canine distemper virus; canine parainfluenza type 2; canine parvo virus - misc. vaccines or anti sera - canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus vaccine-viral active 0.0 p; canine parainfluenza type 2 vaccine-viral active 0.0 p; canine parvo virus vaccine-viral active 0.0 p - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 2 | canine distemper | canine parainfluenza | canine parvovirus | parvovirus

FLUARIX VACCINE Singapore - Engels - HSA (Health Sciences Authority)

fluarix vaccine

glaxosmithkline pte ltd - influenza virus (nh) a/california/7/2009 (h1n1)pdm09 - like strain - injection - 15 mcg haemagglutinin/0.5 ml

Bexsero Europese Unie - Engels - EMA (European Medicines Agency)

bexsero

gsk vaccines s.r.l. - outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant neisseria meningitidis group b fhbp fusion protein, recombinant neisseria meningitidis group b nada protein, recombinant neisseria meningitidis group b nhba fusion protein - meningitis, meningococcal - meningococcal vaccines - active immunisation against invasive disease caused by neisseria meningitidis serogroup-b strains.,

Celvapan Europese Unie - Engels - EMA (European Medicines Agency)

celvapan

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccines - prophylaxis of influenza caused by a(h1n1)v 2009 virus.celvapan should be used in accordance with official guidance.

Nobilis Influenza H5N2 Europese Unie - Engels - EMA (European Medicines Agency)

nobilis influenza h5n2

intervet international bv - inactivated whole avian influenza virus antigen of h5n2 subtype (strain a/duck/potsdam/1402/86) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.efficacy has been evaluated on the basis of preliminary results in chickens. reduction of clinical signs, mortality and excretion of virus after challenge were shown by three weeks after vaccination.serum antibodies could be expected to persist for at least 12 months after administration of two doses of vaccine.

Nobilis Influenza H5N6 Europese Unie - Engels - EMA (European Medicines Agency)

nobilis influenza h5n6

intervet international bv - inactivated whole avian influenza virus antigen of h5 subtype (strain h5n6, a/duck/potsdam/2243/84) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.reduction of clinical signs, mortality and excretion of virus after challenge with a virulent h5n1 strain, were shown by two weeks after a single dose vaccination.serum antibodies have been shown to persist in chickens for at least 7 months and studies performed with other vaccine strains show that serum antibodies would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine.

Nobilis Influenza H7N1 Europese Unie - Engels - EMA (European Medicines Agency)

nobilis influenza h7n1

intervet international bv - inactivated whole avian influenza virus antigen of h7n1 subtype (strain, a/ck/italy/473/99) - immunologicals for aves - chicken; ducks - for active immunisation of chickens and ducks against avian influenza type a, subtype h7n1.efficacy has been evaluated on the basis of preliminary results in chickens and ringed teals.in chickens, reduction of clinical signs, mortality, excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.in ducks, reduction of excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.although it has not been investigated with this particular ai vaccine strain, studies performed with other strains show that protective levels of serum antibody titres would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine. the duration of immunity in ducks is unknown.